Cyclacel Pharmaceuticals Культура компании

Prof. David Glover FRSE serves as Chief Scientist at Cyclacel Pharmaceuticals, Inc. (formerly Cyclacel Group Plc). Prof. Glover served as Chief Scientist for Polgen Division of Cyclacel Pharmaceuticals, Inc. and Cyclacel Limited. Prof. Glover joined Cyclacel Group Plc in November 1999. He is Arthur Balfour Professor of Genetics. He also serves as Director of Cancer Research UK Cell Cycle Genetics Research Group. He served as Professor of Molecular Genetics at the University of Dundee. He also served as Professor and Head of Biochemistry at Imperial College, London. Prof. Glover discovered and named the Polo and Aurora mitotic protein kinases and co-ordinated the former European Drosophila Genome Project, the European academic consortium contributing to sequencing the fruit fly genome. Prof. Glover serves as Chairman in the Department of Genetics at the University of Cambridge. He is a member of the European Molecular Biology Oncology and has authored over 200 publications and patents.

Dr. Judy H. Chiao MD has been Vice President of Clinical Development and Regulatory Affairs at Cyclacel Pharmaceuticals Inc., (formerly, Xcyte Therapies Inc.) since May 13, 2005 and serves as its Chief Medical Officer. Dr. Chiao joined Cyclacel in December, 2004. Previously, She served as Vice President, Oncology Clinical Research and Development at Aton Pharma Inc., a wholly owned subsidiary of Merck & Co. Prior to Aton's acquisition by Merck she was responsible for leading the clinical development of SAHA, a histone deacetylase inhibitor, in Phase II development for hematologic and solid tumor indications. She was a Senior Medical Reviewer, Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), where she was the agency's primary reviewer for a range of oncology drugs and regulatory subjects. She also presented the FDA's views in several New Drug Application reviews at Oncology Drug Advisory Committees. Dr. Chiao is responsible for the design and implementation of clinical trials and regulatory strategies pertaining to Cyclacel's drug portfolio. She was a Member of FDA working groups of health-related quality of life, chemoprevention and oncology disease endpoints. She presented the FDA's views in several New Drug Application reviews at Oncology Drug Advisory Committees (ODAC). In addition to her FDA position, she was an attending physician at the Clinical Center of the National Cancer Institute and the National Navy Medical Center where she participated in clinical research and patient care. Dr. Chiao held a Research Fellowship in Molecular Pharmacology at Sloan Kettering Institute for Cancer Research and a Clinical Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center, both in New York. She is a Member of a number of FDA related working groups and also a Core Member of the Pharsight-FDA Cooperative Research and Development Agreement (CRADA) on clinical trial simulation and population pharmacokinetic analysis software for drug development. She is a Board-Certified Medical Oncologist. Dr. Chiao earned her Bachelor of Science in Chemistry (Summa Cum Laude) at Columbia University, New York and her Medical degree from Harvard Medical School. Her Internship and Residency in Internal Medicine was carried out at Columbia-Presbyterian Medical Center, New York.

Mr. Paul McBarron serves as the Chief Operating Officer, Chief Financial Officer, Executive Vice President of Finance and Secretary at Cyclacel Pharmaceuticals, Inc. (formerly, Xcyte Therapies Inc.) and served as its Executive Vice President of Finance & Administration. Mr. McBarron serves as an Australia Director of Freyssinet SAS. He has 16 years of experience as a Financial Executive with several pharmaceutical companies. He joined Cyclacel Group PLC in January 2002. He served as Chief Financial Officer and Principal Accounting Officer of Cyclacel Group PLC. He served as an Executive Officer of Ernst & Young LLP. Since 1996, Mr. McBarron served as a Senior Member of the Finance team at Shire Pharmaceuticals plc, where he served as Director of Corporate Finance and Group Financial Controller. Mr. McBarron was previously employed in various financial positions at Sterling Drug and SmithKline Beecham Limited. He has been an Executive Director of Cyclacel Pharmaceuticals, Inc since March 2006. He qualified as a Chartered Accountant with Ernst & Young.